■ Bibliografia
  1. Pawlotsky JM et al. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014; 146: 1176–1192
  2. Sulkowski MS et al. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014;370: 211–221
  3. Nelson DR et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotye 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61: 1127-1135
  4. Daklinza. Riassunto delle caratteristiche del prodotto
  5. Welzel TM et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract 37
  6. Hézode C et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract 206
  7. Eley T et al. Daclatasvir exposure does not explain lower sustained virologic response rates in cirrhotic patients with HCV genotype 3 following 12 weeks of daclatasvir plus sofosbuvir treatment, AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract 720
  8. Leroy V et al. All-oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract LB-3
  9. Wyles DL et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl. J Med. 2015;373:714-25
  10. Garimella T, Gandhi Y, Wang R, et al. Daclatasvir exposure alone does not explain HCV relapse in HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir with ritonavir-boosted darunavir in the ALLY-2 study. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract n. 728
  11. Rockstroh JK et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: Interim results of a multicenter compassionate use program. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract 1058
  12. Kwo PY et al. Daclatasvir and sofosbuvir in patients with recurrent HCV following liver transplantation and advanced fibrosis or cirrhosis: United States multicenter treatment protocol. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract 217
  13. Herzer K et al. Daclatasvir in combination with sofosbuvir with or with-out ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: Interim results of a multicenter compassionate use program. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract 252
  14. Fontana RJ et al. Improvement in liver disease parameters following treatment with daclatasvir + sofosbuvir and ribavirin in patients with chronic HCV infection and advanced cirrhosis. AASLD 2015 Nov 13-17. San Francisco, CA, USA. Abstract 706
© Effetti srl